USFDA has recently approved Jakafi (ruxolitinib), which is the first drug approved for the specific treatment of patients with the bone marrow disease myelofibrosis.
What is myelofibrosis. It is a disease in which the bone marrow is replaced by scar tissue resulting in blood cells being made in organs such as the liver and the spleen. This disease is marked by an enlarged spleen, anemia, decreased white blood cells and platelets, and myelofibrosis-related symptoms. Symptoms of myelofibrosis
include fatigue, abdominal discomfort, pain under the ribs, feeling full (satiety), muscle and bone pain, itching, and night sweats.
(Source: www.fda.gov)
What is myelofibrosis. It is a disease in which the bone marrow is replaced by scar tissue resulting in blood cells being made in organs such as the liver and the spleen. This disease is marked by an enlarged spleen, anemia, decreased white blood cells and platelets, and myelofibrosis-related symptoms. Symptoms of myelofibrosis
include fatigue, abdominal discomfort, pain under the ribs, feeling full (satiety), muscle and bone pain, itching, and night sweats.
(Source: www.fda.gov)
